A review of the expanded use of cotrimoxazole in HIV-infected Africans

Southern African Journal of HIV Medicine

Volumn , Issue 24, 2006, Pages 28-32

  Spencer, Dave ^a  

^a Toga Laboratories   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; FANSIDAR; HERBACEOUS AGENT; PENTAMIDINE; PLACEBO; SULFONAMIDE; TRACE ELEMENT; VITAMIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIET SUPPLEMENTATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EPIDEMIC; FEVER; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALARIA; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; REVIEW; SOUTH AFRICA; SUPPORT GROUP; SURVIVAL RATE; TREATMENT PLANNING; UGANDA; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION; ZAMBIA;

EID: 33751567706     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis ofthe published literature. Clinical Infect Dis 2005; 41: 217-224.
2. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1 infected children in Abidjan, Cote d'lvoire. AIDS 2004; 18: 1905-1913.
3. Kapp C. Antiretrovirals give new hope and new life to South Africans. Lancet 2004; 363: 1710.
4. Mills E, Foster BC, van Heeswijk R, et al. Impact of African herbal medicines on antiretroviral metabolism. AIDS 2005; 19: 95-97.
5. World Health Organization. Executive Summary, Consultation on Nutrition and HIV/AIDS in Africa: Evidence, Lessons and Recommendations for Action, Durban, South Africa. 10-13 April 2005. Geneva: WHO.
6. Anglaret X Cherie G, Attia A, et al. and the Cotrlmo-CI study group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'lvoire: a randomized trial. Lancet 1999; 353: 1463-1468.
7. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'lvoire: a randomized controlled trial. Lancet 1999; 353: 1469-1475.
8. Grimwade K, Sturm AW, Nunn AJ, MBatha D, Zungu D, Gilks C. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005; 19: 163-168.
9. Urschel S, Ramos J, Mellado M, etal., and the European PCP-withdrawal Study Group. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under active antiretroviral therapy. AIDS 2005; 19: 2103-2108.
10. World Health Organization. Guidelines for Cotrimoxazole Prophylaxis for HIV-related Infections in Children, Adolescents and Adults in Resource United Settings. Recommendations for a Public Health Approach. Final Draft (2006) World Health Organisation, Geneva, Switzerland. This report is based upon an expert consultation held in May 2005 and available at http:/www.who.int/hiv/pub/meetingreports/ctxprophylaxismeeting.pdf (accessed June 2006).
11. Chintu C, Bhat GJ, Walker AS, et al., on behalf of the CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): randomized placebo-controlled trial. Lancet 2004; 364: 1865-1871.
12. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxir, morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-1434.
13. Huovinen P. Resistance to trimethoprim-sulphamethoxazole. Clinical Infectious Diseases 2001; 32: 1608-1614.
14. Feikin DR, Dowell SF, Nwanyanwu OC, et al. Increased carriage of trimethoprim-sulphamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine-pyramethamine. J Infect Dis 2000; 181: 1501-1505.
15. Martin JN, Rose DA, Hadley WK, et al. Emergence of trimethoprim-sulphamethoxazole resistance in the AIDS era. J Infect Dis 1999; 180: 1809-1818.
16. Song J-H, Jung S-I, Ki HK, etal., for the Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: A study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004; 38: 1570-1578.
17. Scott JAG, Hall AJ, Lowe B, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355: 1225-1230.
18. Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman K. Ineffectiveness of trimethoprim-sulphamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis corinii pneumonia. Clin Infect Dis 2002; 35: 1120-1126.
19. Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarials resistance in southeast Africa: a population-based analysis. Lancet 2003; 361: 1174-1181.
20. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352: 1565-1577.
21. Peikin DR, Dowell SF, Nwanyanwu OC, et al. Increased carriage of trimethoprim-sulfamethoxazole resistant Streptococcus pneumoniae in Malawian children after treatment with sulfadoxine-pryrimethamine. J lnfect Dis 2000; 181: 1501-1505.
22. Anglaret X, Toure S, Ouassa T, Dabis F, N'Dri-Yoman T. Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in West Africa. AIDS 2000; 14: 2628-2629.
23. Mermin J, Lule JR, Ekwaru JP, Pitter C. Should cotrimoxaozle prophylaxis be taken by all adults with HIV in Africa? AIDS 2005; 19: 845-846.
24. Ruffini DD, Madhi SA. The high burden of Pneumacystis carinii pneumonia in Africa HIV-1 infected children hospitalized for severe pneumonia. AIDS 2002; 16: 105-112.
25. Fisk DT, Mesnick S, Kazazjian PH. Pneumocystis carinil pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clinical Infectious Diseases 2003; 36: 70-78.
26. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36: 652-662.
27. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not clihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180: 1969-1978.
28. Kazanjian P, Armstrong W, Hassler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182: 551-557.
29. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jiroveci dihydropteroate synthase gene mutations. AIDS 2005; 19: 801-805.
30. Helweg-Larsen J, Benfield TL, Eugeg-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumacystis corinii clihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999; 354: 1347-1351.
31. Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumacystis carinii dihydropteroate synthase gene an outcome of P. corinii pneumonia in patents with HIV-1: a prospective study. Lancet 2001; 358: 545-549.
32. Meshnick SR. Drug-resistant Pneumacystis carinii. (Editorial.) Lancer 1999; 354; 1318-1319.
33. Yazdanpanah Y. Losina E, Anglaret X, et al., for the Global AJDS Policy Model Investigators. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patents with HIV/AIDS in Cote d'lvoire: a trial-based analysis. AIDS 2005; 19: 1299-1308.
34. Mermin J, Lule J, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005; 19: 1035-1042.
35. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367: 1256-1261.
36. Watera C, Todd J, Muwonge R, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/ AIDS clinic in Uganda. JAcquir Immune Defic Syndr 2006; 42: 373-378.
37. Chintu C, Mudenda V, Lucas S, et al., for the UNZA-UCUMS Project Paediatric Postmortem Study Group. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002; 360: 985-990.
38. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Anthony Hart C, Molyneux M. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children. Lancet 2000; 355: 369-373.
39. Walter J, Mwiya M, Scott N, et al. Cotrimoxazole prophylaxis and adverse birth outcomes among HIV-infected women in Lusaka, Zambia. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006, Denver, Colorado. Abstract 126.
40. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-1429.
41. Duncombe C, Kerr S, Ungsechapand C, et al., and the HIV-NAT Study Group. Immune recovery and stopping cotrimoxazole prophylaxis in Thai patients treated with NNRTI-based HAART for 216 weeks. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006, Denver, Colorado. Abstract 784.
42. Nachman S, Gona P, Darker W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115: 488-494.
43. Urschela S, Ramosb J, Melladob M, et al., and the European PCP-withdrawal Study Group. Withdrawal of Prieumocystis jiroveci prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005: 19: 2103-2108.